insights_auto
Outlook: 37.7% bullish·11.3% bearish
Go to analysischevron_right
BMY:NYSE
Bristol-Myers Squibb Co
56,67 $
arrow_downward
-1,58%(-0,91) 1D
57,18 $
arrow_upward
+0,90% (+0,51)todayPre-market
Closed: 13 հոկ, 16:00:04 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMY...
Open
57,78 $
High
58,02 $
Low
56,15 $
Mkt. cap
115,76 մլրդ
Avg. vol.
11,95 մլն
Volume
2,95 հզր
Dividend
4,45%
Quarterly dividend
0,63 $
Ex-dividend date
02 հոկ, 2026 թ.
P/E ratio
12,48
52-wk high
68,64 $
52-wk low
42,52 $
EPS
4,54 $
Beta
0,19
Shares outstanding
2,04 մլրդ
No. of employees
32 հզր
Open
57,78 $
High
58,02 $
Low
56,15 $
Mkt. cap
115,76 մլրդ
Avg. vol.
11,95 մլն
Volume
2,95 հզր
Dividend
4,45%
Quarterly dividend
0,63 $
Ex-dividend date
02 հոկ, 2026 թ.
P/E ratio
12,48
52-wk high
68,64 $
52-wk low
42,52 $
EPS
4,54 $
Beta
0,19
Shares outstanding
2,04 մլրդ
No. of employees
32 հզր
News stories
From web sources and news partners
BioSpace
·
51 րոպե առաջ
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
MarketBeat
·
2 ժամ առաջ
Bristol Myers Squibb Company $BMY Shares Sold by Perpetual Ltd
ad-hoc-news.de
·
4 ժամ առաջ
Bristol Myers Squibb reports two Phase 3 updates: stock pre-market at EUR 50.67
The Motley Fool
·
12 ժամ առաջ
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32,5 հզր
Founded1887
HeadquartersՆյու Յորք, Նյու Յորք, Միացյալ Նահանգներ
Sector-
Websitebms.com